)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Hansa Biopharma
Hansa Biopharma (HNSA) investor relations material
Hansa Biopharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary11 Nov, 2026
Executive summary
Completed the €115m SERB Idefirix licensing transaction for Europe and MENA; the €110m upfront payment received in July strengthened liquidity and advanced the transition of European responsibilities.
Q3 priorities included US launch preparation, presentation of ConfIdeS and PAES data, and submission of an FDA IND for HNSA-5487 in GBS.
Financial highlights
Q3 revenue was SEK 143.0m versus SEK 30.8m in Q3 2025: SEK 121.6m license revenue, SEK 20.8m supply and service revenue, and SEK 0.6m contract revenue.
Q3 operating loss was SEK 138.6m versus SEK 147.6m; net loss was SEK 178.5m versus SEK 148.3m, reflecting higher financial expense and the SERB inventor compensation charge.
Operating cash flow was SEK 964.4m versus SEK -106.9m; cash and equivalents were SEK 1,337.2m at September 30, 2026.
Outlook and guidance
Idefirix PDUFA date is December 19, 2026; US commercialization and product availability are planned for Q1 2027, subject to FDA approval.
EMA filing to convert Idefirix to full marketing authorization is planned for Q4 2026; SERB owes a further €5m upon EMA acceptance.
First patient enrollment in the 16-patient HNSA-5487 GBS Phase 2a study is anticipated in Q1 2027; a pivotal Phase 3 plan depends on Phase 2a results.
Current cash is expected to support operations well into 2028.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hansa Biopharma
- Strong transplant data and late-2026 regulatory catalysts underpin a broader IgG-cleaving pipeline.HNSA
Corporate presentation - Rapid IgG-cleaving platform drives clinical success, market expansion, and strong financial outlook.HNSACorporate presentation
- €115–150M licensing deal, strong trial data, and improved cash position drive strategic progress.HNSAQ2 2026
- Rapid IgG-cleaving platform drives breakthroughs in transplantation, gene therapy, and rare diseases.HNSACorporate presentation
- Imlifidase enables transplants for highly sensitized patients, with U.S. launch expected in 2027.HNSACMD 2026
- EU-approved Idefirix and a robust pipeline position the company for global growth in rare disease therapies.HNSAÖkonomisk Ugebrev presentation
- Imlifidase enables transplants for highly sensitized patients, transforming access and outcomes.HNSAKOL event
- Imlifidase plus IVIg accelerates recovery in severe GBS, outperforming IVIg alone in early improvement.HNSAStatus Update
- Strong Idefirix sales, pipeline advances, and new funding extend cash runway into 2026.HNSAQ2 2024
Next Hansa Biopharma earnings date
Fireside chat17 Nov, 2026
Hansa Biopharma
Next Hansa Biopharma earnings date
Fireside chat17 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Hansa Biopharma AB, a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. It develops recombinant IgG endopeptidase/CD26 in Hx-CD26 for IgG-mediated autoimmune indications; and antibody drug conjugates (ADCs) in hu2m14 that targets EGF receptor mutations. The company also develops ADCs against CD56 positive cancers in naxitamab; and multiple bispecific antibodies to meet the needs of the various target populations across hematological cancers under pre-clinical development program. In addition, it involves in developing enzyme platform technology to facilitate the development of antibody therapies by inhibiting unwanted immune reactions; and facilitates bone marrow transplantation between genetically distinct individuals.